This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Healthcare
Healthcare, the world's largest industry, is transforming faster than ever. The focus on outcomes based medicine and optimal health management of populations will result in major seismic shifts. Modernization and reform measures are being employed globally by public and private sector organizations to meet the growing need for healthcare. New technologies are being created, offering enormous promise to improve care delivery.
Our Transformational Health practice serves all key industry stakeholders through partnership models that provide access to high-quality content and our global team of industry experts. The practice includes Visionary Health, Life Sciences, Advanced Medical Technologies and Connected Health, focusing on evolving healthcare technologies and covering the entire industry spectrum
-
21 Aug 2020 | Global
Hybridization of Clinical Trial Designs Reviving Global CRO Market Post-pandemic, 2019–2024
Patient-centric and Safety-focused Logistical Solutions will Create New Growth Opportunities
In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new...
$4,950.00 -
12 Aug 2020 | North America
Strategic Commercial Partnerships Transforming the Global Biobanking Market, 2020–2026
Precision Medicine Applications and Value-based Data Pricing with Pharma and Health-tech to Trigger Market Growth
The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment. The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compou...
$4,950.00 -
12 Aug 2020 | North America
New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019–2025
AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities
Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregive...
$4,950.00 -
24 Jul 2020 | North America
Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024
Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies
With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies,...
$4,950.00 -
07 Jul 2020 | Global
Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations
Emerging Chimeric Antigen Receptor (CAR) T-cell Therapy Platforms
This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.
$4,950.00 -
05 May 2020 | North America
FROST RADAR™: Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020
Benchmarking Future Growth Potential
Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...
$4,950.00 -
28 Apr 2020 | Global
Breakthrough Innovations Enhancing Gut Microbial Health
Empowering Medical, Academic and Industrial Communities Through Expert Advice Across Multiple Scientific Disciplines
Overall Impact of Breakthrough Innovations in Gut Microbial Health Covered in this Research - Microbiome expertise: Meeting translational research needs from medical, academic and industrial communities through deep diving know-how and expertise across multiple scientific platforms - Nutrition and therapeutic fields: Enabling precision medicine an...
$4,950.00 -
31 Jan 2020 | North America
Predictions for the Global Life Sciences Industry, 2020
COVID-19 Pandemic will Drive New Digital-tech Adoption in Drug Discovery and Testing Services, and Federal Funding will Encourage Stronger Product Pipelines
The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...
$1,500.00 -
27 Jan 2020 | Global
Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022
Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth
The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...
$4,950.00 -
10 Jan 2020 | Asia Pacific
Growth Insights on China’s Pharmaceutical Industry, Forecast to 2025
Expedited Regulatory Reviews, Accompanied by Surging Novel Drug Pipelines and a Realigned Distribution System will Propel the Chinese Pharma Industry
With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...
$10,000.00
